drugset / Trial / NCT05208060

Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

NCT05208060 ↗

Phase 1/2 Unknown 48 enrolled Inmunotek S.L.
RandomizedParallel-groupDouble-blindOther

Summary

A mechanistic clinical trial with the aim to evaluate whether MV130 can induce the expression of a particular immune response (trained immunity) in peripheral blood cells. Therefore, the investigators are not evaluating efficacy in any disease or medical condition but rather assessing the immunological effect in immunogenicity of MV130 in healthy volunteers.

Timeline

Start
2023-09-01
Primary completion
2025-01-30
Completion
2025-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MV130 Vaccine — Other

Indications

No indication recorded.